The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)
Filter results
| Date | Title | Content | |
|---|---|---|---|
| 21/10/2025 | On business and financial situation | The Company releases the press release in relation to the announcement of the collaboration with Roche for the manufacture of a new medicine in development | |
| 2/10/2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2025 | |
| 29/09/2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | |
| 29/09/2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | |
| 24/07/2025 | On P&L | The Company releases the first half 2025 financial results presentation | |
| 24/07/2025 | On P&L | The Company releases the press release related to the first half of 2025 financial results | |
| 4/07/2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2025 | |
| 3/07/2025 | Other relevant information | The Company informs about the dividends payment. | |
| 18/06/2025 | Announcement of general shareholders’ meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | |
| 8/05/2025 | On business and financial situation | ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID) |